Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-negative Breast Cancer”

845 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 845 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Study completedNCT03184090
What this trial is testing

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

Who this might be right for
Metastatic Breast Cancer
MedSIR 33
Testing effectiveness (Phase 2)Looking for participantsNCT07766018
What this trial is testing

Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 70
Large-scale testing (Phase 3)Study completedNCT01564056
What this trial is testing

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Who this might be right for
Breast Cancer
UNICANCER 1,989
Testing effectiveness (Phase 2)Study completedNCT00234403
What this trial is testing

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT07153757
What this trial is testing

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University 2,934
Testing effectiveness (Phase 2)Study completedNCT02273973
What this trial is testing

Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Who this might be right for
Breast Cancer
Genentech, Inc. 334
Early research (Phase 1)Ended earlyNCT05576077
What this trial is testing

TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerColorectal CancerUveal Melanoma+3 more
Turnstone Biologics, Corp. 31
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Large-scale testing (Phase 3)Active Not RecruitingNCT05104866
What this trial is testing

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Who this might be right for
Breast Cancer
AstraZeneca 732
Early research (Phase 1)Active Not RecruitingNCT04993430
What this trial is testing

HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

Who this might be right for
ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)UnknownNCT04488107
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Who this might be right for
Breast Neoplasms
Ahon Pharmaceutical Co., Ltd. 78
Testing effectiveness (Phase 2)WithdrawnNCT01814865
What this trial is testing

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Who this might be right for
Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
British Columbia Cancer Agency
Not applicableEnded earlyNCT01856036
What this trial is testing

Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers

Who this might be right for
Breast Cancer
Saint John's Cancer Institute 2
Testing effectiveness (Phase 2)Study completedNCT02718144
What this trial is testing

Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer

Who this might be right for
Breast Neoplasms
Pantarhei Oncology B.V. 12
Testing effectiveness (Phase 2)Study completedNCT02463032
What this trial is testing

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Who this might be right for
ER+ and AR+ Breast Cancer
GTx 136
Not applicableEnded earlyNCT01957514
What this trial is testing

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+2 more
University of Washington 31
Testing effectiveness (Phase 2)Ended earlyNCT02000375
What this trial is testing

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)

Who this might be right for
Metastatic BreastcancerEstrogen Receptor Positive Breast CancerEstrogen Receptor Negative Neoplasm+3 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 20
Next Page